^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Lung Non-Small Cell Squamous Cancer |
| Drug: | erlotinib (EGFR inhibitor) + telisotuzumab vedotin (ABBV-399) (Microtubule inhibitor, c-MET-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
An open-label, multicenter, phase I study of ABBV-399 (telisotuzumab vedotin, teliso-V) as monotherapy (T) and in combination with erlotinib (T+E) in non-small cell lung cancer (NSCLC)
Excerpt:
...50 pts received ≥1 dose of T; 8 of 23 (35%) pts on T+E were EGFR M+ and c-MET+. Rate of c-MET+ among screened NSCLC pts with adenocarcinoma and squamous (Sq) histologies was 64% and 42%, respectively….Safety profiles between T treatment schedules were comparable...Promising activity was seen for T+E in EGFR M+ and c-MET+ NSCLC...
DOI:
10.1093/annonc/mdy292.006
Trial ID:
